ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

INO Inovio Pharmaceuticals Inc New

1.8487
0.0037 (0.20%)
21 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Inovio Pharmaceuticals Inc New NASDAQ:INO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0037 0.20% 1.8487 1.81 1.85 1.85 1.75 1.79 1,350,365 00:59:50

INOVIO to Present at Upcoming Scientific Conferences

01/10/2024 1:00pm

PR Newswire (US)


Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart


From Sep 2024 to Dec 2024

Click Here for more Inovio Pharmaceuticals Charts.

PLYMOUTH MEETING, Pa., Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences:

(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)

AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy
Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO
Abstract Title: Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways
Date and Time: October 19, 2024, 6:00 - 8:15pm ET
Location: Boston, MA

ISV Congress 2024
Oral presentation and poster by Dr. Michael Sumner, Chief Medical Officer at INOVIO
Abstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP)
Date and Time: October 22, 2024, 4:20pm KST
Location: Seoul, Korea

Fall Voice
Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development at INOVIO
Abstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP)
Date and Time: October 25October 26, 2024
Location: Phoenix, AZ

World Vaccine Congress Europe
Presentation and panel discussion by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development at INOVIO
Track: Pre-Congress Workshop on Platform Technologies
Date and Time: October 28, 2024, 10:00am CET
Location: Barcelona, Spain

Abstracts from these conferences will be made available on INOVIO's website following each presentation.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conferences-302263723.html

SOURCE INOVIO Pharmaceuticals, Inc.

Copyright 2024 PR Newswire

1 Year Inovio Pharmaceuticals Chart

1 Year Inovio Pharmaceuticals Chart

1 Month Inovio Pharmaceuticals Chart

1 Month Inovio Pharmaceuticals Chart